格隆汇8月19日丨诺诚健华(688428.SH)公布2025年半年度报告，报告期实现营业收入7.31亿元，同比增 长74.26%；归属于上市公司股东的净利润-3009.14万元；基本每股收益-0.02元。营业收入较上年同期增 加74.26%，主要系奥布替尼销售量持续增加及达成授权许可确认相关收入所致，其中药品销售收入增 长53.47%。 ...

诺诚健华医药有限公司2025 年半年度报告 公司代码：688428 公司简称：诺诚健华 诺诚健华医药有限公司 2025 年半年度报告 1 / 196 诺诚健华医药有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 无 七、 是否存在公司治理特殊安排等重要事项 √适用 □不适用 公司治理特殊安排情况： 二、 重大风险提示 公司是一家以卓越的自主研发能力为核心驱动力的高科技创新生物医药企业，拥有全面的研 发、生产和商业化能力，专注于肿瘤和自身免疫性疾病等存在巨大未满足临床需求的领域，在全 球市场内开发具有突破性潜力的同类首创或同类最佳药物。2025 年上半年，公司实现归母净利润 -0.30 亿元，相较去年同期（归母净利润-2.62 亿元）亏损缩窄 88.51%。公司归母净利润仍为负， 主要由于新药研发、生产、商业化是一个周期长、投资大、风险高的过程，公司在药物早期发现、 临床前研究、临床开发、注册、生产、商业化推广等多个环节持续投入。报告期内，公司持续加 大在新技术平台建设 ...

| A | 股代码：688428 | 股简称：诺诚健华 A | 公告编号：2025-033 | | --- | --- | --- | --- | | 港股代码：09969 | | 港股简称：诺诚健华 | | 诺诚健华医药有限公司 关于持股 5%以上股东权益变动 触及 1%刻度的提示性公告 投资者 King Bridge Investments Limited 及其一致行动人 Success Growth Limited 保证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 1、身份类别 | | □控股股东/实际控制人及其一致行动人 | | --- | --- | | 投资者及其一致行动 | | | √其他 | 5%以上大股东及其一致行动人 | | 人的身份 | | | | □合并口径第一大股东及其一致行动人（仅适用于无控 | 1 股股东、实际控制人） □其他______________（请注明） 2、信息披露义务人信息 | 信息披露义务人名称 | | | 投资者身份 | 统一社会信用代码 | | - ...

每经AI快讯，8月19日，诺诚健华公告称，公司拟以自有资金不超过人民币4.76336亿元收购高新科控持 有的广州诺诚健华7%的剩余全部股权。收购完成后，公司将持有广州诺诚健华100%的股权。该交易不 构成关联交易，亦不构成重大资产重组，无需提交股东大会审议。目前，交易尚未完成，最终交易价格 和能否摘牌成功存在不确定性。 ...

诺诚健华公告，公司计划以自有资金不超过人民币4.76亿元收购广州高新区科技控股集团有限公司持有 的控股子公司广州诺诚健华医药科技有限公司7%的剩余全部股权。交易完成后，公司将持有广州诺诚 健华100%的股权。此举旨在增强对子公司的控制力，提高运营和决策管理效率，优化资源配置，助力 公司实现2战略发展目标。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 總收益由截至2024年6月30日止六個月的人民幣419.7百萬元增加74.3%至截至 2025年6月30日止六個月的人民幣731.4百萬元，主要是由於奧布替尼銷量增 長強勁及來自Prolium的許可收益。奧布替尼的收益由截至2024年6月30日止六 個月的人民幣417.0百萬元增加52.8%至截至2025年6月30日止六個月的人民幣 637.3百萬元，是由於覆蓋範圍拓寬及治療患者增加所致。 – 2 – 總運營開支（包括銷售及分銷開支、研發開支及行政開支）由截至2024年6月 30日止六個月的人民幣669.5百萬元增加17.8%至截至2025年6月30日止六個月 的人民幣788.5百萬元。該變動主要因以下各項導致：(i)銷售及分銷開支由截 至2024年6月30日止六個月的人民幣157.2百萬元增至截至2025年6月30日止六 個月的人民 ...

Group 1 - The core point of the article highlights the performance of the Huatai Fuhua Medical Service Flexible Allocation Mixed A Fund, which has shown significant returns over various time frames, including a 69.10% return over the past six months and a 65.45% return year-to-date, ranking first in its category [1] - The fund's latest net value is reported at 1.9920 yuan, reflecting a decrease of 0.75% [1] - The fund's top ten stock holdings account for a total of 68.66%, with notable investments in companies such as Heng Rui Pharmaceutical (9.90%) and Ke Lun Pharmaceutical (9.03%) [1] Group 2 - The Huatai Fuhua Medical Service Flexible Allocation Mixed A Fund was established on June 18, 2015, and as of June 30, 2025, it has a total scale of 2.915 billion yuan [1] - The fund manager, Zhang Wei, has a strong background in biomedical studies and extensive experience in the pharmaceutical sector, having held various positions in research and fund management [2]

Core Viewpoint - The company, 诺诚健华, reported a significant increase in total revenue and a substantial reduction in losses for the six months ending June 30, 2025, primarily driven by strong sales of 奥布替尼 and licensing revenue from Prolium [1][2] Financial Performance - Total revenue increased by 74.3% to RMB 730 million compared to the same period last year [1] - Revenue from 奥布替尼 rose by 52.8% from RMB 417 million to RMB 637 million, attributed to an expanded coverage and an increase in treated patients [1] - Losses decreased by 86.7% from RMB 268 million to RMB 35.6 million during the same period [1] - Cash and cash equivalents stood at approximately RMB 7.7 billion as of June 30, 2025, providing the company with a robust financial position to accelerate clinical development and invest in competitive product lines [1] Product Development and Milestones - The company achieved significant milestones in product line advancement, including the approval of 奥布替尼 for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [2] - The combination therapy of坦昔妥单抗 and 来那度胺 was approved for adult patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplantation (ASCT) [2] - The BCL-2 inhibitor ICP-248 (mesutoclax) entered two registrational clinical studies, and the company's proprietary ADC platform made significant breakthroughs with the first IND submission and clinical trial approval [2] Strategic Partnerships and Global Expansion - The company expanded its global footprint through strategic collaborations, including a partnership with Prolium in January 2025 to explore the global potential of a CD3×CD20 bispecific antibody [2] - The company remains committed to fostering global partnerships to enhance innovation, maximize the value of its product lines, and support long-term development [2] Commercial Execution - Strong commercial execution is evident with increased market penetration and significant revenue growth from 奥布替尼, highlighting the company's ability to translate scientific innovation into sustainable business performance [2]

Core Insights - The company reported a significant increase in total revenue, rising 74.3% to RMB 730 million for the six months ending June 30, 2025, primarily driven by strong sales of Oubatinib and licensing revenue from Prolium [1] - The loss for the period decreased by 86.7% to RMB 35.6 million, compared to a loss of RMB 268 million for the same period ending June 30, 2024 [1] - The company has a robust cash position of approximately RMB 7.7 billion as of June 30, 2025, allowing for flexible clinical development and investment in competitive product lines [1] Product Development and Milestones - The company achieved significant milestones in product line advancement, including the approval of Oubatinib for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [2] - The combination therapy of Tanshituzumab and Lenalidomide was approved for adult patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplantation (ASCT) [2] - The BCL-2 inhibitor ICP-248 (mesutoclax) entered two registrational clinical studies, and the company's proprietary ADC platform made significant breakthroughs with the first IND submission and clinical trial approval [2] Strategic Partnerships and Market Execution - The company expanded its global footprint through strategic collaborations, including a partnership with Prolium in January 2025 to explore the global potential of a CD3×CD20 bispecific antibody [2] - The commercial execution remains strong, with increased market penetration and substantial revenue growth for Oubatinib, highlighting the company's ability to translate scientific innovation into sustainable business performance [2]

诺诚健华(09969)发布截至2025年6月30日止6个月中期业绩，该集团取得收益人民币7.31亿元(单位下 同)，同比增加74.26%;期内经调整亏损1550.4万元，同比减少93.62%;母公司拥有人应占亏损3009.1万 元，同比减少88.51%;每股亏损0.02元。 公告称，收入增加主要是由于奥布替尼销量增长强劲及来自Prolium的许可收益。奥布替尼的收益由截 至2024年6月30日止6个月的4.17亿元增加52.8%至截至2025年6月30日止6个月的 6.37亿元，是由于覆盖 范围拓宽及治疗患者增加所致。 ...